H.R. 9421

119 HR 9421 IH: Ban Abortion by Mail Act
 U.S. House of Representatives
 2026-06-24
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  2d Session  H. R. 9421  IN THE HOUSE OF REPRESENTATIVES   June 24, 2026   Mrs. Biggs of South Carolina  (for herself,  Mr. Fry , and  Mr. Norman ) introduced the following bill; which was referred to the  Committee on Energy and Commerce    A BILL
To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
1.
Short title
This Act may be cited as the   Ban Abortion by Mail Act  .
2.
Findings
The Congress finds the following:
(1)
Mifepristone can only be prescribed by a health care provider certified under the Mifepristone Risk Evaluation and Mitigation Strategies (REMS) Program.
(2)
Medical experts have advised that patients should be closely observed for signs and symptoms of adverse effects.
(3)
The purpose of Risk Evaluation and Mitigation Strategies (REMS) is to ensure the benefits of a drug outweigh its risks, especially for drugs with serious safety concerns.
3.
Health care provider REMS-certified status
(a)
In-Person visit required
Any REMS-certified provider that knowingly prescribes, dispenses, or administers mifepristone or any other abortion drug without an in-person visit with the patient for whom such drug is prescribed shall lose REMS-certified status, with respect to such drug, for a period of not less than 2 years.
(b)
License in patient’s State required
Any REMS-certified provider that knowingly prescribes, dispenses, or administers mifepristone or any other abortion drug to a patient residing in a State where the provider does not have a medical license shall lose REMS-certified status, with respect to such drug, for a period of not less than 2 years.
(c)
Reporting
The Secretary shall, on an annual basis, submit to Congress a report listing each REMS-certified provider who has lost REMS-certified status due to—
(1)
a violation of this section; or
(2)
improper or unsafe prescribing of mifepristone or any other abortion drug.
(d)
Definitions
In this section:
(1)
Abortion drug
The term  abortion drug  means any drug, substance, or combination of drugs or substances that is intended for use or that is in fact used (irrespective of how the product is labeled) to intentionally kill the unborn child of a woman known to be pregnant, or to intentionally terminate the pregnancy of a woman known to be pregnant, with an intention other than—
(A)
to produce a live birth;
(B)
to remove a dead unborn child; or
(C)
to treat an ectopic pregnancy.
(2)
REMS-certified status
The term  REMS-certified status  means, with respect to mifepristone or any other abortion drug, the certification of a REMS-certified provider by the Secretary to dispense such drug pursuant to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ).
(3)
REMS-certified provider
The term  REMS-certified provider  means a health care professional who has successfully completed the FDA’s Risk Evaluation and Mitigation Strategy (REMS) certification program for prescribing mifepristone.
(4)
Secretary
The term  Secretary  means the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs.